Involvement of the subthalamic nucleus in glutamatergic compensatory mechanisms
- PMID: 10336685
- DOI: 10.1046/j.1460-9568.1999.00627.x
Involvement of the subthalamic nucleus in glutamatergic compensatory mechanisms
Abstract
The purpose of the present study was to investigate whether the subthalamic nucleus (STN) was implicated in the glutamatergic compensatory mechanisms which have been shown to mask the parkinsonian motor abnormalities at the end of the presymptomatic period in experimental parkinsonism. Using multiunit electrophysiological recordings, we follow changes of activity occurring in the STN and in both the pars externalis and the pars internalis of the globus pallidus of monkeys chronically intoxicated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), according to a protocol designed to mimic the gradual evolution of dopaminergic neuronal death. STN activity augmented significantly in the course of treatment, even before the first appearance of clinical signs (P < 0.01). This result would indicate that the STN, which increases its level of activity even before the end of the presymptomatic period, is principally responsible for the instigation of glutamatergic compensatory mechanisms which allow the maintenance of the striatal dopaminergic homeostasis.
Similar articles
-
The primate subthalamic nucleus. III. Changes in motor behavior and neuronal activity in the internal pallidum induced by subthalamic inactivation in the MPTP model of parkinsonism.J Neurophysiol. 1994 Aug;72(2):521-30. doi: 10.1152/jn.1994.72.2.521. J Neurophysiol. 1994. PMID: 7983516
-
The primate subthalamic nucleus. II. Neuronal activity in the MPTP model of parkinsonism.J Neurophysiol. 1994 Aug;72(2):507-20. doi: 10.1152/jn.1994.72.2.507. J Neurophysiol. 1994. PMID: 7983515
-
Lesion of the subthalamic nucleus for the alleviation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism in the primate.Mov Disord. 1991;6(4):288-92. doi: 10.1002/mds.870060404. Mov Disord. 1991. PMID: 1758446
-
The role of the subthalamic nucleus in the origin of hemiballism and parkinsonism: new surgical perspectives.Adv Neurol. 1997;74:235-47. Adv Neurol. 1997. PMID: 9348418 Review. No abstract available.
-
The subthalamic nucleus: a possible target for stereotaxic surgery in Parkinson's disease.Mov Disord. 1993 Oct;8(4):421-9. doi: 10.1002/mds.870080402. Mov Disord. 1993. PMID: 8232351 Review.
Cited by
-
Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease.J Neurosci. 2001 Sep 1;21(17):6853-61. doi: 10.1523/JNEUROSCI.21-17-06853.2001. J Neurosci. 2001. PMID: 11517273 Free PMC article.
-
The roles of connectivity and neuronal phenotype in determining the pattern of α-synuclein pathology in Parkinson's disease.Neurobiol Dis. 2022 Jun 15;168:105687. doi: 10.1016/j.nbd.2022.105687. Epub 2022 Mar 10. Neurobiol Dis. 2022. PMID: 35283326 Free PMC article. Review.
-
Metabotropic glutamate receptor 5 antagonist protects dopaminergic and noradrenergic neurons from degeneration in MPTP-treated monkeys.Brain. 2011 Jul;134(Pt 7):2057-73. doi: 10.1093/brain/awr137. Brain. 2011. PMID: 21705423 Free PMC article.
-
RGS9-2 negatively modulates L-3,4-dihydroxyphenylalanine-induced dyskinesia in experimental Parkinson's disease.J Neurosci. 2007 Dec 26;27(52):14338-48. doi: 10.1523/JNEUROSCI.4223-07.2007. J Neurosci. 2007. PMID: 18160641 Free PMC article.
-
Neuronal activity in the subthalamic nucleus modulates the release of dopamine in the monkey striatum.Eur J Neurosci. 2009 Jan;29(1):104-13. doi: 10.1111/j.1460-9568.2008.06565.x. Epub 2008 Dec 12. Eur J Neurosci. 2009. PMID: 19087163 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous
